86 related articles for article (PubMed ID: 21150798)
1. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests.
Price RA; Frank RG; Cleary PD; Goldie SJ
Med Care; 2011 Feb; 49(2):132-8. PubMed ID: 21150798
[TBL] [Abstract][Full Text] [Related]
2. Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of US primary care physicians.
Han PK; Klabunde CN; Breen N; Yuan G; Grauman A; Davis WW; Taplin SH
Med Care; 2011 Feb; 49(2):139-48. PubMed ID: 21206294
[TBL] [Abstract][Full Text] [Related]
3. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers.
Lee JW; Berkowitz Z; Saraiya M
Obstet Gynecol; 2011 Jul; 118(1):4-13. PubMed ID: 21691157
[TBL] [Abstract][Full Text] [Related]
4. [Cervical cancer screening and the place of the HPV test in 2012].
Bosch FX; Bergeron C
Ann Pathol; 2012 Nov; 32(5 Suppl):S22-3. PubMed ID: 23127928
[No Abstract] [Full Text] [Related]
5. Human Papillomavirus Testing by Veterans Administration Women's Health Providers: Are They Adhering to Guidelines?
Hallett LD; Gerber MR
J Womens Health (Larchmt); 2018 Feb; 27(2):179-182. PubMed ID: 28885082
[TBL] [Abstract][Full Text] [Related]
6. Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.
Malo TL; Perkins RB; Lee JH; Vadaparampil ST
Sex Transm Dis; 2016 Jul; 43(7):438-44. PubMed ID: 27322046
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of adolescent female reactions to direct-to-consumer advertising: the case of the Human Papillomavirus (HPV) Vaccine.
Leader AE; Cashman R; Voytek CD; Baker JL; Brawner BM; Frank I
Health Mark Q; 2011 Oct; 28(4):372-85. PubMed ID: 22054031
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
Kellen E; Benoy I; Vanden Broeck D; Martens P; Bogers JP; Haelens A; Van Limbergen E
Int J Cancer; 2018 Aug; 143(4):861-868. PubMed ID: 29569715
[TBL] [Abstract][Full Text] [Related]
9. Perceived effectiveness of HPV test as a primary screening modality among US providers.
Cooper CP; Saraiya M
Prev Med; 2015 Sep; 78():33-7. PubMed ID: 26116889
[TBL] [Abstract][Full Text] [Related]
10. Abuses in human papillomavirus DNA testing.
Castle PE
Obstet Gynecol; 2011 Jul; 118(1):1-3. PubMed ID: 21691156
[No Abstract] [Full Text] [Related]
11. [Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR].
Sahiner F; Gümral R; Sener K; Yiğit N; Dede M; Yapar M; Kubar A
Mikrobiyol Bul; 2012 Oct; 46(4):624-36. PubMed ID: 23188576
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
14. Change in Provider Beliefs Regarding Cervical Cancer Screening Intervals After an Educational Intervention.
Benard VB; Greek A; Roland KB; Hawkins NA; Lin L; Saraiya M
J Womens Health (Larchmt); 2016 May; 25(5):422-7. PubMed ID: 27096534
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer screening from Pap smear to human papillomavirus DNA testing.
Jin XW; Xu H
Compr Ther; 2001; 27(3):202-8. PubMed ID: 11569320
[TBL] [Abstract][Full Text] [Related]
16. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
Sawaya GF
Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
[No Abstract] [Full Text] [Related]
17. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists.
Perkins RB; Anderson BL; Gorin SS; Schulkin JA
Am J Prev Med; 2013 Aug; 45(2):175-81. PubMed ID: 23867024
[TBL] [Abstract][Full Text] [Related]
18. Cervical Cancer Screening with Human Papillomavirus Self-Sampling Among Transgender Men in El Salvador.
Maza M; Meléndez M; Herrera A; Hernández X; Rodríguez B; Soler M; Alfaro K; Masch R; Conzuelo-Rodríguez G; Obedin-Maliver J; Cremer M
LGBT Health; 2020; 7(4):174-181. PubMed ID: 32407149
[No Abstract] [Full Text] [Related]
19. Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.
Roland KB; Soman A; Benard VB; Saraiya M
Am J Obstet Gynecol; 2011 Nov; 205(5):447.e1-8. PubMed ID: 21840492
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening.
Huang YK; You SL; Yuan CC; Ke YM; Cao JM; Liao CY; Wu CH; Hsu CS; Huang KF; Lu CH; Twu NF; Chu TY
Br J Cancer; 2008 Mar; 98(5):863-9. PubMed ID: 18283313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
